POINT Biopharma Global Inc. (PNT) PT Lowered to $14 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts PNT Hot Sheet
Price: $12.50 --0%
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Join SI Premium – FREE
Truist Securities analyst Nicole Germino lowered the price target on POINT Biopharma Global Inc. (NASDAQ: PNT) to $14.00 (from $22.00) while maintaining a Buy rating.
You May Also Be Interested In
- CareDx, Inc (CDNA) PT Raised to $81 at BTIG
- Waste Connections Inc. (WCN) PT Raised to $215 at UBS
- Guardant Health (GH) PT Raised to $210 at BTIG, remains Top Pick
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
